Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-11-01
|
| Series: | Clinical Interventions in Aging |
| Subjects: | |
| Online Access: | https://www.dovepress.com/changing-from-bevacizumab-to-ranibizumab-in-age-related-macular-degene-peer-reviewed-article-CIA |
| _version_ | 1818843179530584064 |
|---|---|
| author | Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al. |
| author_facet | Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al. |
| author_sort | Dimitrios A Karagiannis |
| collection | DOAJ |
| description | Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, GreeceObjective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD).Design: Retrospective case series.Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), and fluorescein angiography were performed at the baseline examination and then monthly. Chi-square test was used for statistical analysis.Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better than the initial thickness and the value following the bevacizumab course. No major ocular or systemic side effects were noted.Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab contributed to a transient “instability” in the eye which may have triggered the large subretinal hemorrhage. There is insufficient experience reported in the literature in switching from one agent to another. A prospective study with controls is necessary to determine whether it is safe to change from one medication to another.Keywords: age-related macular degeneration, bevacizumab, ranibizumab, subretinal hemorrhage |
| first_indexed | 2024-12-19T04:53:45Z |
| format | Article |
| id | doaj.art-5b4a909ac95b4d3da9972cb7c9110698 |
| institution | Directory Open Access Journal |
| issn | 1178-1998 |
| language | English |
| last_indexed | 2024-12-19T04:53:45Z |
| publishDate | 2009-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Interventions in Aging |
| spelling | doaj.art-5b4a909ac95b4d3da9972cb7c91106982022-12-21T20:35:17ZengDove Medical PressClinical Interventions in Aging1178-19982009-11-01Volume 44574613776Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?Dimitrios A KaragiannisIoannis D LadasEfstratios Parikakiset al.Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, GreeceObjective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD).Design: Retrospective case series.Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), and fluorescein angiography were performed at the baseline examination and then monthly. Chi-square test was used for statistical analysis.Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better than the initial thickness and the value following the bevacizumab course. No major ocular or systemic side effects were noted.Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab contributed to a transient “instability” in the eye which may have triggered the large subretinal hemorrhage. There is insufficient experience reported in the literature in switching from one agent to another. A prospective study with controls is necessary to determine whether it is safe to change from one medication to another.Keywords: age-related macular degeneration, bevacizumab, ranibizumab, subretinal hemorrhagehttps://www.dovepress.com/changing-from-bevacizumab-to-ranibizumab-in-age-related-macular-degene-peer-reviewed-article-CIAAge related macular degenerationBevacizumabRanimizumabsubretinal haemorrhage |
| spellingShingle | Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? Clinical Interventions in Aging Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage |
| title | Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? |
| title_full | Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? |
| title_fullStr | Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? |
| title_full_unstemmed | Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? |
| title_short | Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? |
| title_sort | changing from bevacizumab to ranibizumab in age related macular degeneration is it safe |
| topic | Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage |
| url | https://www.dovepress.com/changing-from-bevacizumab-to-ranibizumab-in-age-related-macular-degene-peer-reviewed-article-CIA |
| work_keys_str_mv | AT dimitriosakaragiannis changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT ioannisdladas changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT efstratiosparikakis changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT etal changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe |